Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 355 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Care pathway Clear all

Conditions: High-Risk Prostate Cancer
Interventions: Capivasertib, abiraterone acetate; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
Interventions: KYMRIAH, YESCARTA; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Advance Care Planning
Interventions: Nurse Navigator Pathway, Usual Care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Asheboro, North Carolina • Claremont, North Carolina • Conover, North Carolina + 3 more

Conditions: Chronic Migraine, Migraine Disorders, Headache Disorders, Headache, Migraine
Interventions: Osteopathic Manipulative Therapy (OMT), Standard of care; Procedure · Other
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)
Interventions: Electronic medical record-based care pathway; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV-1-infection
Interventions: PrEPsmart mobile app, Truvada; Device · Drug
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoporosis, Arthroplasty Complications, Fragility Fracture
Interventions: Surgeon-Initiated Bone Health Referral Pathway; Combination Product
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Ventral Hernia, Ventral Incisional Hernia, Post Operative Pain
Interventions: PT Group, Usual Care; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Arrhythmia, Atrial Fibrillation
Interventions: Quality improvement; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more

Conditions: Breast Neoplasms
Interventions: Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Interventions: ENCompaSS (Education, Navigated Care, and Supported Self-Management) with VA Stepped Usual Care; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Surgery, Quality Improvement, Perioperative Care, ERAS
Interventions: ERAS perioperative care, Standard perioperative care, Noninvasive hemodynamic monitoring; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pedal Pad Atrophy, Diabetes Mellitus
Interventions: Year A Pathway, Year B Pathway; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mental Health
Interventions: IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vertigo, Dizziness
Interventions: VRT Care; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Peoria, Illinois • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Kidney Diseases, Chronic Kidney Diseases, End Stage Renal Disease, End Stage Renal Disease on Dialysis, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: IHI Breakthrough Collaborative Model; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Arvada, Colorado • Thornton, Colorado • Westminster, Colorado + 9 more

Conditions: Type 2 Diabetes
Interventions: Produce Prescription; Behavioral
Lead sponsor: Gretchen Swanson Center for Nutrition; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Fort Wayne, Indiana • New Orleans, Louisiana + 2 more

Conditions: Acneiform Drug Eruption, Acneiform Eruptions
Interventions: Isotretinoin, Doxycycline, Blood specimen collection, Photographs of Rash, Questionnaires, Stool Specimen collection; Drug · Procedure · Other + 1 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 39 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Coronary Syndrome
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 88
States / cities: Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more

Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions: ctDNA-Guided Treatment Strategy; Device
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Sarcoma
Interventions: Enhanced Recovery After Surgery; Procedure
Lead sponsor: Joshua Lawrenz; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19 Pneumonia
Interventions: PF-06650833, Matching Placebo; Drug
Lead sponsor: Giovanni Franchin, M.D, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions: Systemic therapy, StrataNGS; Other · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Integrated Multidisciplinary Patient and Family Advance Care Planning Trial

Osteopathic Manipulative Treatment and Migraine Headaches

Automated Clinical Pathway for Inflammatory Bowel Disease Care

PrEPsmart 2-1-1 Pilot

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery

Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

Comparing Non-Medicine Strategies for Improving Low Back Pain

Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project

Fat Grafting for Pedal Fat Pad Atrophy in Diabetics

Novel Methods for Implementing Measurement-Based Care for Youth in Low-resource Environments

Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)

Pathways Project: Kidney Supportive Care

Pathway for Produce Prescriptions in Diabetes Management

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Enhanced Recovery After Surgery in Extremity Sarcoma

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer